Leadership Team

WILLIAM LIS
Chief Executive Officer

Mr. Lis joined Portola in 2008 and was appointed chief executive officer in May 2010. During this time, Portola has advanced several novel compounds into clinical development, successfully raised over $600 million in private and public financings – including an initial public offering in 2013, and executed multiple partnerships for its programs. Portola’s two wholly-owned thrombosis programs, betrixaban and andexanet alfa, are in late-stage clinical trials, and its wholly-owned oncology agent, cerdulatinib, is in a Phase 2 trial in hematologic cancers. Prior to serving as CEO, he served as chief operating officer and chief business officer. He has over 20 years of experience in biopharmaceutical commercialization, corporate development and management. Mr. Lis previously held positions at Scios, Inc. (a Johnson & Johnson Company) from 2004 to 2007 where he last served as vice president, business and commercial operations. He led successful in-licensing and commercial launch operations for Xarelto® (rivaroxaban). Prior to joining Scios, he was director of marketing and new products for Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.), which included the launch of Integrilin® (eptifibatide). At Rhone-Poulenc Rorer, he was involved in the U.S. sales launch and commercialization of several products, including Lovenox® (enoxaparin). Mr. Lis holds a B.S. from the University of Maryland.

Back to top

JOHN T. CURNUTTE, M.D., Ph.D.
Executive Vice President, Research and Development

Dr. John T. Curnutte joined Portola as executive vice president, research and development, in 2011. Prior to joining Portola, he served as chief executive officer of 3-V Biosciences, a private start-up company founded in 2007 with the goal of developing host-directed antiviral small molecules. Before that, he served as president at Schering-Plough Biopharma (formerly DNAX Research Institute and now Merck Research Laboratories) where he led the drug discovery and early development efforts for biologic therapeutics. During his time with Schering-Plough, eight therapeutic entities progressed into development, including five small molecules and one gene therapy construct, in the immunology and oncology therapeutic areas. Earlier in his career, he held several senior management positions at Genentech during which he oversaw that company’s immunology discovery program. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. He received an undergraduate degree in biochemistry and molecular biology from Harvard University and an M.D. and a Ph.D. in biological chemistry from Harvard Medical School. He is currently an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff, where he continues to consult on patients with primary immunodeficiencies. Dr. Curnutte is a member of the board of directors of diaDexus, Inc., a company focused on cardiovascular diagnostics.

Back to top

MARDI C. DIER
Executive Vice President, Chief Financial Officer

Mardi C. Dier joined Portola in August 2006 and has served as executive vice president and chief financial officer since November 2013. Ms. Dier oversees the finance and accounting, investor relations, information technology and facilities departments. Prior to that, she was senior vice president and chief financial officer. Ms. Dier has taken Portola public and successfully raised approximately $760 million in public and private equity offerings. Previously, she served as vice president of investor relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a director in the West Coast investment banking practice at Prudential Securities, where she focused on client development, equity underwriting and mergers and acquisitions for biotechnology and other life sciences companies. Ms. Dier was previously at KPMG Peat Marwick in the audit department. She holds a B.S. in biology from Stanford University and an M.B.A. from The Anderson School at the University of California, Los Angeles. In 2013, Ms. Dier was recognized as one of the Most Influential Women in Bay Area Business by the San Francisco Business Times and was a finalist for its Bay Area CFO of the Year Award.

Back to top

TAO FU
Executive Vice President, Chief Commercial and Business Officer

Mr. Fu joined Portola Pharmaceuticals in June 2015 as executive vice president, chief commercial and business officer. He is responsible for the company’s commercial operations and business development. Mr. Fu has 18 years of experience in business development, commercial strategy and management consulting in the biopharmaceutical industry with industry-leading companies. Prior to joining Portola, he was vice president and head of mergers and acquisitions and alliance management at Bristol-Myers Squibb. In that position, he was responsible for the company’s corporate development, alliance management and venture activities. Prior to that, he was vice president, business development at Janssen, the pharmaceuticals group of Johnson & Johnson. During his tenure there, he was responsible for over 20 business development transactions, including the execution of the U.S. license and collaboration agreement with Bayer for Xarelto® (rivaroxaban). Earlier in his career, he held positions at Scios Inc. (acquired by Johnson & Johnson), McKinsey & Company and Becton Dickinson. Mr. Fu holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies at Tsinghua University and is a chartered financial analyst (CFA).

Back to top

JANICE CASTILLO
Senior Vice President, Regulatory Affairs and Quality Assurance

Janice Castillo has served as vice president of regulatory affairs at Portola since September 2007. She has 30 years of broad-based regulatory experience in the biotechnology and pharmaceutical industries, which includes recombinant proteins, monoclonal antibodies, small molecules and gene therapy. Ms. Castillo served as a consultant to the industry prior to joining Portola. From 2003 to 2006 she was vice president of regulatory affairs and GLP/GCP compliance at Abgenix, Inc., providing regulatory guidance for several development and research projects and collaboration projects. Prior to Abgenix, she was vice president of regulatory affairs and quality assurance at Avigen, Inc. From 1998 to 2000, Ms. Castillo served as vice president of regulatory affairs and compliance at Elan Pharmaceuticals. From 1983 to 1998, she held positions of increasing responsibility in regulatory affairs at Genentech, Inc. Ms. Castillo started her career in regulatory affairs at Ortho Pharmaceuticals in 1977, working in both the small molecule and immunobiology divisions. She has a B.S. in biology from Duquesne University in Pittsburgh.

Back to top

ALEXANDER M. GOLD, M.D., F.A.C.C.
Senior Vice President, Clinical Development

Dr. Alexander M. Gold joined Portola as senior vice president, clinical development, in 2013. Prior to joining Portola, he served as vice president, head of clinical development at Reata Pharmaceuticals from 2012 to 2013. While there, he led clinical development of novel drugs targeting advanced kidney disease, chronic inflammation and oxidative stress. Before Reata, he held a number of leadership positions at Astra Zeneca from 2001 to 2012, most recently as executive director and development leader for Brilinta®, Crestor® and Onglyza®. In this capacity, he was responsible for clinical and strategic development activities in the United States, leading regulatory interactions with the Food and Drug Administration, and leading scientific, regulatory and medical affairs. He also led large global outcomes trials, including JUPITER. He led global cross-functional teams responsible for development, regulatory and commercial strategy and execution. He published in peer-reviewed journals, such as The Lancet, Circulation, Journal of the American Journal of Cardiology and Clinical Therapeutics. He received a B.A. in biology from Brandeis University and an M.D. from Harvard Medical School. He completed his internship, residency and cardiology fellowship at Beth Israel Deaconess Hospital/Harvard Medical School, and conducted translational and clinical research as a fellow in cardiovascular research at the Harvard Clinical Research Institute. Dr. Gold is a board-certified cardiologist.

Back to top

MARK W. GOSSETT
Senior Vice President, Global Marketing

Mr. Gossett joined Portola in September 2013 as senior vice president of commercial. He has more than 25 years of commercial experience building successful teams, brands and franchises across multiple high-value therapeutic areas. Mr. Gossett has significant thrombosis expertise and a proven track record in strategic marketing, product launch and commercialization, including leading commercialization efforts at Aventis for the anticoagulant Lovenox® (enoxaparin), which he helped grow to become a $1 billion drug in the United States. Prior to Portola, he founded Greenhill Solutions, LLC, a healthcare commercialization consultancy, where he developed and executed commercialization plans for a variety of healthcare-related companies, primarily focused in the specialty/critical care setting. His work there led to the founding of vima medical, llc to identify and develop healthcare applications for existing proprietary sensor technologies. Earlier in his career, he served as a senior commercial executive at Tibotec Therapeutics (HIV/virology), Endo Pharmaceuticals (pain management) and Sanofi-Aventis Pharmaceuticals (thrombosis, bone metabolism, arthritis and infectious disease). Mr. Gossett earned a B.S. in agriculture from Purdue University and an M.B.A. from the Wharton School, University of Pennsylvania.

Back to top

STACY MARKEL
Senior Vice President, Human Resources

Stacy Markel joined Portola as senior vice president of human resources in 2015. Ms. Markel is leading Portola’s human resources department and overseeing its strategy to foster an employee culture that emphasizes quality, collaboration, transparency, productivity, goal attainment, empowerment and a shared purpose. Prior to joining Portola, Ms. Markel was the senior vice president of human resources at Actelion, where she was a member of the executive leadership team. She was instrumental in the successful growth of the organization and positioning culture as a key strategic advantage in attracting and retaining talent. Under her leadership, Actelion was a Bay Area Best Place to Work winner seven consecutive years. Ms. Markel joined Actelion in 2002 after a ten-year career at Roche Pharmaceuticals in sales and sales management. She received a B.A. in International Relations from the University of California, Davis, and is a member of the Healthcare Business Women’s Association and the Bay Area HR Executive Forum, as well as a board member for Biotech Organization and Leadership Development.

Back to top

ANJALI PANDEY, Ph.D.
Senior Vice President, Medicinal Chemistry and Chemical Development

Dr. Anjali Pandey joined Portola in November 2003 and has served as senior vice president of medicinal chemistry and chemical development since July 2015 and vice president chemistry since April 2006. Dr. Pandey is responsible for the overall leadership of medicinal chemistry, process research and development, manufacturing of active pharmaceutical ingredient and drug products for clinical candidates. Dr. Pandey is leading clinical and development efforts for Portola’s oral, dual Syk-JAK kinase inhibitor cerdulatinib, and development of Portola’s intellectual property portfolio. Prior to Portola, she held senior research positions at Millennium Pharmaceuticals and COR Therapeutics. Dr. Pandey has over 20 years of biotechnology experience with hands-on involvement in all stages of drug development, from initial lead identification to Phase 3 clinical trials. Dr. Pandey is the principal inventor of cerdulatinib, the Syk-selective inhibitor PRT2607, and the flt-3 receptor tyrosine kinase inhibitor tandutinib. She played a key role in the discovery and development of Portola’s Factor Xa inhibitor betrixaban and the P2Y12 receptor antagonist elinogrel. Dr. Pandey has published over 30 scientific publications and reviews and is co-inventor on 40 issued U.S. patents and 30 U.S. patent applications. She holds an M.S. from the Indian Institute of Technology in Kanpur, India, and a Ph.D. from Southern Illinois University. Dr. Pandey completed her postdoctoral fellowship in bioorganic chemistry at SRI International (formerly Stanford Research Institute).

Back to top

R. ANDREW RAMELMEIER, Ph.D.
Senior Vice President, Technical Operations, Biologics

Dr. R. Andrew “Andy” Ramelmeier has served as senior vice president of biologics technical operations since October 2014. He has 20 years of experience and a strong foundation in the development and manufacturing of biopharmaceuticals, including monoclonal antibodies, vaccines, enzymes and other therapeutic proteins. Dr. Ramelmeier was responsible for the licensure of several commercial products, process improvements to several more commercial products, and the design, construction and operation of 6 biologics production facilities, totaling over $400MM in investment. His technical expertise spans from cell culture and fermentation through purification, formulation and parenteral fill/finish. Prior to joining Portola, Dr. Ramelmeier served as vice president, global manufacturing and facilities, at BioMarin Pharmaceutical, a biotechnology company specializing in enzyme replacement therapies. In that position, he was responsible for bulk manufacturing of three commercial biologics products, clinical manufacturing of pipeline product candidates, and facilities maintenance and engineering. Previously, Dr. Ramelmeier was vice president, process sciences at Centocor /J&J, where he was responsible for technical support of J&J’s BioPharm manufacturing plants. He held roles of increasing responsibility in R&D at Centocor and in BioProcess R&D at Merck & Co. Dr. Ramelmeier received a B.S. in chemical engineering from Johns Hopkins University and a Ph.D. in chemical engineering from the University of California, Berkeley. He conducted post-doctoral work at the Institute for Enzyme Technology in Germany.

Back to top

MICHELE D. BRONSON, Ph.D.
Vice President, Program Management

Dr. Bronson joined Portola in November 2014 as vice president of program management and with over 15 years of experience at start-up to medium-size biotech companies. Dr. Bronson was most recently Vice President of regulatory and quality at Labrys Biologics developing an anti-CGRP monoclonal antibody for the prevention of migraine. Labrys was acquired by Teva Pharmaceuticals for $825 million in July 2014. Prior to Labrys, Dr. Bronson was Vice President of Regulatory, Quality and Project Management at Medivation, Inc., where she oversaw the development of their prostate cancer compound (enzalutamide) from pre-IND stage through FDA approval. Dr. Bronson served in roles of increasing responsibility in regulatory affairs at Chiron Corporation, until its acquisition by Novartis in 2006. Dr. Bronson received her Ph.D. in molecular biology from UT Southwestern Medical School.

Back to top

MY-LIEN BUI
Vice President, Quality

My-Lien Bui joined Portola in 2016 as vice president of quality. Ms. Bui is responsible for developing and implementing Portola’s quality programs, including quality assurance, worldwide process excellence programs and total quality management throughout the organization so the company can meet global regulatory, medical/health and legislative standards. My-Lien was most recently head of quality assurance at Adverum Biotechnologies (formerly Avalanche Biotechnologies), where she provided leadership for the development and implementation of their quality systems. Prior to that, she was the executive director of quality assurance at Pharmacyclics. She has also led and worked with quality teams at Chiron, Aviron, Scios, Genentech, and SciClone. My-Lien holds an MBA from St. Mary’s College of California and a B.A. in Biology from the University of California, Berkeley.

Back to top

PAMELA CONLEY, Ph.D.
Vice President, Biology

Dr. Pamela Conley joined Portola in November 2003 and is vice president, biology, where she is involved in clinical development efforts for andexanet alfa, Portola’s recombinant Factor Xa inhibitor antidote. Prior to Portola, she was a director in biology at Millennium, where she was responsible for the basic research and drug discovery efforts for the P2Y12 program, as well as identification of novel platelet targets through expression profiling studies. Dr. Conley joined COR Therapeutics in 1991, where she initially worked on platelet integrins and then initiated the program to identify novel inhibitors of platelet ADP receptors and study their signaling pathways. Dr. Conley’s group was responsible for cloning and identification of the P2Y12 receptor, which was published in Nature in 2001. She is the author of more than 45 scientific publications and reviews, which have been published in such peer-reviewed journals as Nature, Nature Medicine, Science and Journal of Clinical Investigation. She is as an inventor on multiple patents. Dr. Conley received her B.A. in biochemistry from the University of Texas at Austin and her Ph.D. in biochemistry from the University of California, Berkeley, after which she worked as a postdoctoral fellow at Stanford University at both the Carnegie Institute for Plant Biology and the Howard Hughes Medical Institute at Stanford Medical School.

Back to top

JEET MAHAL
Vice President, Business Development

Jeet Mahal joined Portola in 2008 and was appointed vice president, business development in January 2013. He has been head of business development at Portola since 2010 and is responsible for in-licensing, out-licensing and alliance management activities across the company’s development portfolio. Prior to Portola, Mr. Mahal was director, business and new product development at Scios Inc. (a Johnson & Johnson Company), where he led commercial life cycle activities for Xarelto and commercial analysis for U.S. cardiovascular in-licensing. Prior to Scios, Mr. Mahal was a managing consultant for Navigant Consulting’s Life Sciences practice. He began his career as a development scientist at COR Therapeutics, where he worked on a number of the company’s pipeline products, including Integrilin, taking it from Phase 2 to New Drug Application. Mr. Mahal holds a B.A. in biological sciences from the University of California at Berkeley, an M.B.A. from the Fuqua School of Business at Duke University, a master’s degree in biology from Illinois Institute of Technology, and a master’s degree in engineering, computer science from North Carolina State University.

Back to top

W. RICHEY NEUMAN, M.D., M.P.H., F.A.C.P.
Vice President, Medical Affairs

Dr. W. Richey Neuman joined Portola as vice president of medical affairs in October 2015. Dr. Neuman was previously vice president and head of medical affairs at Hyperion Therapeutics and vice president of medical affairs for Teva Pharmaceuticals. Prior to that, he was executive director and therapeutic area lead for vaccines at Pfizer, where he was in the leadership group in charge of Pfizer’s global vaccine strategy. Dr. Neuman was assistant professor of clinical medicine at the University of Pennsylvania School of Medicine from 1997 to 2005 and was director of the General Medicine Fellowship Program. During his career, Dr. Neuman has also served as coordinator of the Veterans’ Persian Gulf Illnesses Registry in Connecticut, and as the University City Homeless Health Clinic medical director at the University of Pennsylvania.

Dr. Neuman obtained his medical degree from the Medical College of Pennsylvania and completed his residency in general internal medicine at the Oregon Health Sciences University. Following residency, he was a Robert Wood Johnson Clinical Scholar at Yale University School of Medicine, followed by additional training as an Ambulatory Care Fellow at Yale. Dr. Neuman received a B.S. from Stanford University, a Master’s of Public Health from the UC Berkeley, and worked as a toxicologist/epidemiologist at the State of California Department of Health.

Back to top

RANDY ST. LAURENT
Vice President, Sales

Randy St. Laurent joined Portola in 2015 as vice president of sales. Randy is responsible for building and leading the new sales organization for Portola. Randy is a proven sales leader with over 25 years of sales management and hospital selling experience, which includes multiple cardiovascular medicines. He was vice president of sales at Theravance Biopharma, where he was responsible for building out Theravance’s sales infrastructure. Prior to that, he was the vice president of sales at Cadence Pharmaceuticals where he built and led a strong sales force and developed successful sales training programs. From 2001 to 2007, Randy was the vice president of sales and marketing and commercial development at Scios Inc. (a Johnson & Johnson Company), where he specialized in the congestive heart failure product Natrecor. Randy was regional sales director for the Genentech cardiovascular sales team that launched Activase. Randy holds a B.S. in Business Administration and Marketing from Ohio State University.

Back to top

*Cerdulatinib is a proposed International Nonproprietary Name (pINN).